Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

Figure 2

Cell cycle arrest induced by MP470. A549, LNCaP and PC-3 cells were treated with DMSO, 10 μM of Erlotinib, or MP470, or IM alone or the combinations for 32 hr and then treated with or without nocodazole for an additional 16 hr. Cells were harvested, fixed, treated with RNase, and then labeled with propidium iodide, and analyzed by flow cytometry (X-axis: DNA content, Y-axis: cell numbers). MP470 induced a G1 arrest in A549 and LNCaP but not in PC-3 cells.

Back to article page